These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 36185276)

  • 81. Upregulation of NKG2D ligands in acute lymphoblastic leukemia and non-Hodgkin lymphoma cells by romidepsin and enhanced in vitro and in vivo natural killer cell cytotoxicity.
    Satwani P; Bavishi S; Saha A; Zhao F; Ayello J; van de Ven C; Chu Y; Cairo MS
    Cytotherapy; 2014 Oct; 16(10):1431-40. PubMed ID: 24856896
    [TBL] [Abstract][Full Text] [Related]  

  • 82. hIL-15 gene-modified human natural killer cells (NKL-IL15) augments the anti-human hepatocellular carcinoma effect in vivo.
    Jiang W; Zhang C; Tian Z; Zhang J
    Immunobiology; 2014 Jul; 219(7):547-53. PubMed ID: 24721706
    [TBL] [Abstract][Full Text] [Related]  

  • 83. [Expression and significance of NKG2D ligands in 13 tumor cell lines].
    Wang YP; Zhang C; Niu JF; Zhang JH; Xu XQ; Wang JF
    Ai Zheng; 2008 Mar; 27(3):243-8. PubMed ID: 18334111
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Synergistic integration of histone deacetylase inhibitors apparently enhances the cytokine-induced killer cell efficiency in multiple myeloma via the NKG2D pathway.
    Pu J; Sharma A; Liu T; Hou J; Schmidt-Wolf IG
    Clin Transl Immunology; 2024; 13(3):e1500. PubMed ID: 38529413
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Simultaneous knockdown of multiple ligands of innate receptor NKG2D prevents natural killer cell-mediated fulminant hepatitis in mice.
    Huang M; Sun R; Wei H; Tian Z
    Hepatology; 2013 Jan; 57(1):277-88. PubMed ID: 22806577
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Major histocompatibility complex class I-related chain A and UL16-binding protein expression on tumor cell lines of different histotypes: analysis of tumor susceptibility to NKG2D-dependent natural killer cell cytotoxicity.
    Pende D; Rivera P; Marcenaro S; Chang CC; Biassoni R; Conte R; Kubin M; Cosman D; Ferrone S; Moretta L; Moretta A
    Cancer Res; 2002 Nov; 62(21):6178-86. PubMed ID: 12414645
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Down-regulation of NKG2D and NKp80 ligands by Kaposi's sarcoma-associated herpesvirus K5 protects against NK cell cytotoxicity.
    Thomas M; Boname JM; Field S; Nejentsev S; Salio M; Cerundolo V; Wills M; Lehner PJ
    Proc Natl Acad Sci U S A; 2008 Feb; 105(5):1656-61. PubMed ID: 18230726
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Adipocytes affect castration-resistant prostate cancer cells to develop the resistance to cytotoxic action of NK cells with alterations of PD-L1/NKG2D ligand levels in tumor cells.
    Xu L; Shen M; Chen X; Zhu R; Yang DR; Tsai Y; Keng PC; Chen Y; Lee SO
    Prostate; 2018 Apr; 78(5):353-364. PubMed ID: 29330929
    [TBL] [Abstract][Full Text] [Related]  

  • 89. IL-2-activated haploidentical NK cells restore NKG2D-mediated NK-cell cytotoxicity in neuroblastoma patients by scavenging of plasma MICA.
    Kloess S; Huenecke S; Piechulek D; Esser R; Koch J; Brehm C; Soerensen J; Gardlowski T; Brinkmann A; Bader P; Passweg J; Klingebiel T; Schwabe D; Koehl U
    Eur J Immunol; 2010 Nov; 40(11):3255-67. PubMed ID: 21061445
    [TBL] [Abstract][Full Text] [Related]  

  • 90. The correlation between NK cell and liver function in patients with primary hepatocellular carcinoma.
    Sha WH; Zeng XH; Min L
    Gut Liver; 2014 May; 8(3):298-305. PubMed ID: 24827627
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Valproic acid upregulates NKG2D ligand expression and enhances susceptibility of human renal carcinoma cells to NK cell-mediated cytotoxicity.
    Yang F; Shao Y; Yang F; Liu M; Huang J; Zhu K; Guo C; Luo J; Li W; Yang B; Shi J; Zheng J
    Arch Med Sci; 2013 Apr; 9(2):323-31. PubMed ID: 23671445
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Failure recovery of circulating NKG2D
    Gao J; Duan Z; Zhang L; Huang X; Long L; Tu J; Liang H; Zhang Y; Shen T; Lu F
    Oncoimmunology; 2016; 5(1):e1048061. PubMed ID: 26942056
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Valproic acid sensitizes pancreatic cancer cells to natural killer cell-mediated lysis by upregulating MICA and MICB via the PI3K/Akt signaling pathway.
    Shi P; Yin T; Zhou F; Cui P; Gou S; Wang C
    BMC Cancer; 2014 May; 14():370. PubMed ID: 24885711
    [TBL] [Abstract][Full Text] [Related]  

  • 94. HER2/HER3 signaling regulates NK cell-mediated cytotoxicity via MHC class I chain-related molecule A and B expression in human breast cancer cell lines.
    Okita R; Mougiakakos D; Ando T; Mao Y; Sarhan D; Wennerberg E; Seliger B; Lundqvist A; Mimura K; Kiessling R
    J Immunol; 2012 Mar; 188(5):2136-45. PubMed ID: 22301547
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Dual targeting of mTORC1/C2 complexes enhances histone deacetylase inhibitor-mediated anti-tumor efficacy in primary HCC cancer in vitro and in vivo.
    Shao H; Gao C; Tang H; Zhang H; Roberts LR; Hylander BL; Repasky EA; Ma WW; Qiu J; Adjei AA; Dy GK; Yu C
    J Hepatol; 2012 Jan; 56(1):176-83. PubMed ID: 21835141
    [TBL] [Abstract][Full Text] [Related]  

  • 96. Epigenetic modulation of neuroblastoma enhances T cell and NK cell immunogenicity by inducing a tumor-cell lineage switch.
    Cornel AM; Dunnebach E; Hofman DA; Das S; Sengupta S; van den Ham F; Wienke J; Strijker JGM; van den Beemt DAMH; Essing AHW; Koopmans B; Engels SAG; Lo Presti V; Szanto CS; George RE; Molenaar JJ; van Heesch S; Dierselhuis MP; Nierkens S
    J Immunother Cancer; 2022 Dec; 10(12):. PubMed ID: 36521927
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Sorafenib plus memory like natural killer cell combination therapy in hepatocellular carcinoma.
    Eresen A; Pang Y; Zhang Z; Hou Q; Chen Z; Yu G; Wang Y; Yaghmai V; Zhang Z
    Am J Cancer Res; 2024; 14(1):344-354. PubMed ID: 38323279
    [TBL] [Abstract][Full Text] [Related]  

  • 98. A Novel Liver Cancer-Selective Histone Deacetylase Inhibitor Is Effective against Hepatocellular Carcinoma and Induces Durable Responses with Immunotherapy.
    Wu B; Tapadar S; Ruan Z; Sun CQ; Arnold RS; Johnston A; Olugbami JO; Arunsi U; Gaul DA; Petros JA; Kobayashi T; Duda DG; Oyelere AK
    ACS Pharmacol Transl Sci; 2024 Oct; 7(10):3155-3169. PubMed ID: 39416967
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Synergistic antitumor activity of artesunate and HDAC inhibitors through elevating heme synthesis
    Chen CP; Chen K; Feng Z; Wen X; Sun H
    Acta Pharm Sin B; 2019 Sep; 9(5):937-951. PubMed ID: 31649844
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Carbon ion (
    Wang J; Dai Z; Miao Y; Zhao T; Gan J; Zhao C; Ran J; Guan Q
    Cancer Lett; 2021 Sep; 521():178-195. PubMed ID: 34492331
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.